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Abstract
Purpose To explore the role of plasmatic platelet-activat-
ing factor acetylhydrolase (PAF-AH), a marker of cardio-
vascular risk, in patients with anti-phospholipid antibodies
(aPL).
Methods PAF-AH activity was assessed in a series of 167
unselected patients screened for aPL in a context of
thrombotic events, risk of thrombosis or obstetric compli-
cations and in 77 blood donors.
Results 116/167 patients showed positive results for at
least one aPL among IgG/IgM anti-prothrombin/phos-
phatidylserine (aPS/PT), anti-cardiolipin (aCL), anti-beta2-
glycoprotein I (ab2GPI) or lupus anticoagulant (LAC),
while 51/167 patients resulted aPL-negative. LAC?
patients disclosed higher PAF-AH than LAC-negative
(22.1 ± 6.4 nmol/min/ml vs. 19.5 ± 4.1 nmol/min/ml;
p = 0.0032), and aPL-negative patients (p = 0.03).
Patients presenting positive IgG ab2GPI disclosed higher
PAF-AH than patients with only IgM ab2GPI-positive
antibodies (23.1 ± 7.2 nmol/min/ml vs. 20.1 ± 5.3 nmol/
min/ml; p = 0.035), as well as than patients showing only
isolated LAC, aCL or aPS/PT (16.9 ± 3.8 nmol/min/ml;
p = 0.003).
Conclusions PAF-AH plasmatic activity is particularly up-
regulated in LAC? and in ab2GPI IgG? patients, possibly
representing an alternative prognostic biomarker for the
therapeutic management of APS patients.
Keywords Platelet-activating factor acetylhydrolase 
Anti-phospholipid syndrome  Anti-beta2-glycoprotein I
antibodies  Anti-prothrombin/phosphatidylserine
antibodies  Lupus anticoagulant  Atherosclerosis
Introduction
Anti-phospholipid syndrome (APS) is a hypercoagulable
disorder clinically displayed by venous or arterial throm-
bosis and/or adverse obstetric events, accompanied by
persistent and elevated levels of anti-phospholipid anti-
bodies (aPL) [1]. According to the 2006 revised interna-
tional classification criteria [2], patients with definite
diagnosis of APS are those presenting positive lupus anti-
coagulant (LAC) and/or one among anti-cardiolipin (aCL)
IgG or IgM or anti-beta2 glycoprotein I (ab2GPI) IgG or
IgM antibodies. However, during the last international
congress on aPL antibodies, the major experts defined the
role of other so-called ‘‘non criteria’’ antibodies, con-
tributing to assess the risk of thrombosis or the identifica-
tion of potential seronegative APS, such as the anti-
prothrombin/phosphatidylserine antibodies (aPS/PT) [3].
Of note, the combination of ab2GPI, aPS/PT and LAC has
demonstrated the best diagnostic accuracy for APS [4] and
aPS/PT were recently recommended as a surrogate for
LAC when specific inhibitors and/or analytical variables
may affect its interpretation [5]. However, no definite
recommendations are available to guide the therapeutic
approach in patients positive only for aPS/PT antibodies.
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Platelet-activating factor acetylhydrolase (PAF-AH) is a
family of enzymes, the most abundant of which is the
plasma form, also called lipoprotein-associated phospho-
lipase A2 (Lp-PLA2) [6]. The plasmatic PAF-AH is con-
stitutively active and circulates bound to LDL, HDL and
other lipoproteins and catalyses the hydrolysis of the sn2
acetate of PAF and PAF mimetics, which are early medi-
ators of inflammation [7]. PAF activates a variety of cells
of the innate immune system promoting migration, adhe-
sion and inflammatory effects. Thus, PAF-AH while
inactivating PAF is considered an important factor in pre-
venting an exaggerated inflammatory response and in
protecting cells from uncontrolled oxidative damage [8].
Several studies reported a significant association
between higher PAF-AH plasmatic activity and the sever-
ity of cardiovascular (CV) disease and identified PAF-AH
as a marker of vascular inflammation and atherosclerotic
plaque instability [9–11].
More and more papers in recent literature emphasize the
relevant link between endothelial dysfunction, atheroscle-
rosis and APS [12–14]. Chronic inflammation is involved
in various stages of development of the atherosclerotic
plaques. Among the key molecules involved in the
atherosclerotic process are heat-shock proteins, oxidized
LDL (oxLDL) and b2GPI. The latter is identified as an
anti-atherogenic agent involved in the atheromatous plaque
formation in APS patients, since it is targeted by the
ab2GPI antibodies, typically associated with APS [15, 16].
In this study we analysed PAF-AH plasmatic activity in
a large series of unselected patients screened for aPL
antibodies in a reference laboratory for the diagnosis of
autoimmune diseases, investigating its association with
different pattern of aPL positivity.
Materials and methods
Patients
The study was conducted in 167 consecutive unselected
patients (124 females and 69 males; mean age:
51 ± 16 years) who were screened for the presence of aPL
at the Laboratory of Immunopathology of the University
Hospital of Udine in the context of routine testing for
thrombotic events, risk of thrombosis or obstetric compli-
cations. Patients were compared to 77 blood donors (BDs;
39 females and 38 males; mean age: 39 ± 13 years)
enrolled at the Transfusion Unit of the same Hospital. All
patients and controls gave their informed consent to the
study according to the Declaration of Helsinki (1964) and
to the Italian legislation (Authorization of the Privacy
Guarantor No. 9, 12th of December 2013).
Methods
The plasmatic PAF-AH activity was assessed by a colori-
metric assay (PAF-AH Assay Kit-Cayman Chemical
Company, Ann Arbor, MI, USA). Briefly, plasma or serum
samples were incubated with the 2-thio PAF substrate, i.e.,
hydrolyzed by PAF-AH at the sn2-position releasing free
thiols detected by DTNB Ellman’s reagent (5,50-dithio-bis-
2-nitrobenzoic acid).
Anti-cardiolipin (aCL) and anti-beta2 glycoprotein I
(ab2GPI) IgG/IgM antibodies were investigated in all
patients, while 125 patients were tested for lupus antico-
agulant and 125 for anti-phosphatidylserine/prothrombin
(aPS/PT) IgG/IgM antibodies. aCL and ab2GpI antibodies
were analysed by chemiluminescence (Zenit RA instru-
ment by A. Menarini Diagnostics, Italy), while aPS/PT
were assayed by Quanta Lite aPS/PT IgG/IgM ELISA kit
(Inova Diagnostics Inc, San Diego, CA). Plasma samples
were tested for the presence of LAC according to the
recommended criteria from the ISTH Subcommittee on
Lupus Anticoagulant-Phospholipid-dependent antibodies
and optimized according to recently published standard-
ization [17, 18]. Total cholesterol, low-density lipoproteins
(LDL), high-density lipoproteins (HDL) and triglycerides
were analysed by diagnostic methods.
Statistic analyses
Quantitative variables were expressed as mean ± standard
deviation and checked for normality distribution by the
Shapiro–Wilk test. Statistical analyses were performed
with GraphPad Prism software. To compare biomarker
serum levels between patients and controls, either Mann–
Whitney or unpaired t test was used when appropriate.
Correlation analyses were performed using the Pearson’s or
the Spearman’s rank correlation coefficient.
Results
PAF-AH plasmatic activity in patients and controls:
correlation with lipid metabolic markers
PAF-AH plasmatic activity in BDs disclosed a mean value
of 15.6 ± 4 nmol/min/ml (range 5.9–28.4). As expected
[11], a significant correlation was found between PAF-AH
and total cholesterol (r = 0.25; p = 0.032), a stronger
direct correlation with LDL (r = 0.46, p\ 0.0001) and a
highly significant inverse correlation with HDL
(r = -0.45, p\ 0.0001). No correlation was found with
age and sex (15.5 ± 5 nmol/min/ml in females vs.
15.7 ± 3.3 nmol/min/ml in males).
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Of the 167 patients undergoing aPL investigation, 116
showed at least one positive aPL among LAC, aCL, ab2GPI
or aPS/PT antibodies, while 51 resulted all negative. PAF-
AH plasmatic activity was markedly more elevated in the
overall patients (19.8 ± 5.5 nmol/min/ml) than in BDs
(p\ 0.0001), but no difference was found between aPL?
and aPL-negative patients (19.9 ± 5.8 nmol/min/ml vs.
19.6 ± 4.7 nmol/min/ml; Fig. 1).
Of note, total cholesterol levels did not differ signifi-
cantly between BDs and the overall patients, nor between
BDs and aPL? patients (188 ± 38 mg/dl vs.
198 ± 42 mg/dl; p = 0.10) and between aPL? and aPL-
negative patients (206 ± 52 mg/dl; p = 0.47). However,
LDL serum levels were higher in aPL-negative patients
than in BDs (127 ± 42 mg/dl vs. 104 ± 35 mg/dl;
p = 0.0073) as well as in aPL? patients (109 ± 35 mg/dl;
p = 0.032 vs. aPL-negative; p = ns vs. BDs).
The significant correlation between PAF-AH activity and
cholesterol, LDL and HDL serum levels persisted in aPL?
patients (r = 0.21, p = 0.041; r = 0.23, p = 0.024 and
r = -0.31, p = 0.0027, respectively), while in aPL-negative
patients it was evident only for LDL (r = 0.29, p = 0.14;
r = 0.25,p = 0.0027 and r = -0.25,p = 0.21, respectively).
PAF-AH plasmatic activity in patients disclosing
distinct pattern of aPL positivity
As shown in Fig. 1, when distinguishing aPL? patients
based on LAC assay, LAC? disclosed higher PAF-AH
than LAC-negative patients (22.1 ± 6.4 nmol/min/ml vs.
19.5 ± 4.1 nmol/min/ml; p = 0.0032). Of note, total
cholesterol levels did not differ between LAC? and LAC-
negative patients (202 ± 39 mg/dl vs. 201 ± 34 mg/dl;
p = ns), as well as LDL (113 ± 39 mg/dl vs.
108 ± 26 mg/dl; p = ns) and HDL serum levels
(60 ± 21 mg/dl vs. 63 ± 21 mg/dl; p = ns). Moreover,
LAC? patients disclosed higher PAF-AH than aPL-nega-
tive patients (p = 0.03), with again no difference with
regard to HDL (62 ± 24 mg/dl in aPL-negative; p = ns)
and LDL (127 ± 42 mg/dl in aPL-negative; p = ns). As
illustrated in Fig. 2, patients presenting ab2GPI IgG?
antibodies disclosed higher PAF-AH plasmatic activity
than patients presenting only ab2GPI IgM? antibodies
(23.1 ± 7.2 nmol/min/ml vs. 20.1 ± 5.3 nmol/min/ml;
p = 0.035), but they did not differ with regard to LDL and
HDL serum levels. Patients who were negative for ab2GPI
IgG or IgM antibodies, but who showed either isolated
LAC or aCL or aPS/PT-positive antibodies demonstrated
significantly lower PAF-AH activities that appeared com-
parable to those measured in BDs (Fig. 2;
16.9 ± 3.8 nmol/min/ml; p = ns vs. BDs; p = 0.003 vs.
ab2GPI IgM?). Total cholesterol, LDL and HDL serum
levels in patients with isolated LAC or aCL or aPS/PT-
positive antibodies did not differ from those measured in
patients with ab2GPI IgM? or IgG? antibodies. Overall,
aPS/PT IgG? patients disclosed PAF-AH activity close to
that of aPS/PT IgM? patients (17.3 ± 3 nmol/min/ml vs.
16.1 ± 3.9 nmol/min/ml; p = ns). Finally, patients
Fig. 1 PAF-AH plasmatic activity in patients and controls. PAF-AH
plasmatic activity was markedly more elevated in the overall patients
(19.8 ± 5.5 nmol/min/ml) than in BDs (p\ 0.0001), but no differ-
ence occurred between aPL-positive and aPL-negative patients
(19.9 ± 5.8 nmol/min/ml vs. 19.6 ± 4.7 nmol/min/ml; p = ns).
LAC-positive patients disclosed higher PAF-AH than LAC-negative
(22.1 ± 6.4 nmol/min/ml vs. 19.5 ± 4.1 nmol/min/ml; p = 0.0032)
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disclosing ab2GPI IgG? antibodies together with aPS/PT
IgG? antibodies tended to show higher PAF-AH activity
than patients disclosing only ab2GPI IgG? antibodies
(23.4 ± 7 nmol/min/ml vs. 21 ± 4.7 nmol/min/ml;
p = ns).
Discussion
Increased PAF-AH expression demonstrated a predictive
role for cardiovascular events in relation to the vulnera-
bility of atherosclerotic plaques. Therefore, PAF-AH
dosage has been proposed in the assessment of CV risk, to
ensure a better stratification of at risk populations [10]. To
date, PAF-AH has never been investigated in the context of
APS patients, or, even less, in patients at risk to develop an
overt APS (i.e. asymptomatic carriers of aPL antibodies,
patients affected by systemic connective tissues diseases).
Our study was originally conducted in a context of
patients routinely screened for APS, demonstrating a sig-
nificant association between the presence of aPL antibod-
ies, LAC and ab2GPI IgG in particular, and PAF-AH up-
regulation in plasma.
Atherosclerosis is definitely recognized as a chronic
inflammatory response to the accumulation of lipoproteins
in the walls of arteries [19]. PAF-AH, produced by
monocytes, macrophages and T lymphocytes, and mainly
associated with LDL, is predominantly expressed in the
necrotic centre of the atherosclerotic plaques and in the
macrophage-rich areas and releases pro-inflammatory
mediators, such as lysophospholipids and oxidized fatty
acids [8].
Besides the presence of LAC, several different targets
of aPL could be determined by a number of analytical
methods, with frequent discordant results, that could
make the laboratory diagnosis of APS extremely com-
plicated. The main role of the ab2GPI antibodies, espe-
cially those specifically targeting domain I [20], is widely
accepted and present results seem to further confirm their
importance with regard to CV risk stratification, since
PAF-AH appeared particularly elevated in ab2GPI-posi-
tive patients and more so in those displaying LAC activity
and carrying the IgG isotype. This particular association
may be explained by the fact that IgG ab2GPI antibodies
are able to recognize the stable complex between oxLDL
and b2GPI, thus facilitating macrophage-derived foam
cell formation in patients with APS [15]. The immune-
pathological mechanisms sustained by oxLDL/b2GPI
complexes are not yet fully understood, but Toll-like
receptor 4 (TLR4) was recently shown to be involved
[15]. TLR4 could be the key player linking PAF-AH up-
regulation to ab2GPI IgG antibodies in APS, as evidenced
by a mouse model of preterm delivery which demon-
strated that PAF effects and signalling depend upon TLR4
stimulation [21].
Lp-PLA2 activity proved to be markedly reduced
in vivo when the enzyme is bound to HDL [8], and this is
in line with our observation that ab2GPI IgG? patients
disclosed higher PAF-AH and lesser HDL than BDs. This
is not true for other subgroups of patients, such as aPL-
negative patients or those presenting only isolated LAC or
aCL or aPS/PT antibodies. Compared to these patients,
PAF-AH plasmatic activity up-regulation in ab2GPI IgG?
cases appeared to be at least partially disconnected from
Fig. 2 PAF-AH plasmatic activity in patients with distinct aPL
positivities. Patients presenting positive ab2GPI IgG antibodies
disclosed higher PAF-AH plasmatic activity than patients presenting
only positive ab2GPI IgM antibodies (23.1 ± 7.2 nmol/min/ml vs.
20.1 ± 5.3 nmol/min/ml; p = 0.035). Patients negative for ab2GPI
IgG or IgM antibodies showing either isolated LAC or aCL or aPS/
PT-positive antibodies (*) demonstrated significantly lower PAF-AH
activity (16.9 ± 3.8 nmol/min/ml; p = 0.003 vs. ab2GPI IgM?)
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the lipoprotein levels and specifically linked to the pres-
ence of such aPL antibodies.
Therefore, PAF-AH up-regulation arose as a specific
thrombotic risk marker in patients carrying ab2GPI anti-
bodies and is not generally associated with other aPL
antibodies possibly implicated in APS manifestations, but
further studies are needed to confirm this observation.
Unfortunately, in two large randomized clinical trials, an
inhibitor of PAF-AH (darapladib) [22, 23] failed to reduce
the risk of major coronary events as compared to placebo.
In addition, it was associated with significantly higher rates
of drug discontinuation and adverse effects. These results
suggested that PAF-AH may be a biomarker of vascular
inflammation, rather than a causal pathway of CV diseases
[23]. Therefore, high PAF-AH activity could reflect a
response to pro-inflammatory stress characteristic both of
atherosclerosis and APS [24].
The leading cause of death in primary and secondary APS
patients are cardiovascular events due to acceler-
ated atherosclerosis, which often progresses more rapidly,
compared with the general population [14]. Some key pro-
inflammatory proteins correlate with APS clinical manifes-
tations [25] and common radiological markers of subclini-
cal atherosclerosis and CV risk were often reported in such
patients [13]. However, to date, besides the presence of aPL
itself, no serological biomarkers specifically associated with
aPL-related pathogenic mechanisms have been identified as
useful to improve the classification of CV risk in aPL?
patients, with and without overt clinical manifestations.
In this scenario, present findings on PAF-AH assume a
relevant place, possibly representing a reliable and
affordable biomarker useful to identify patients at higher
risk in which to take a more cautious therapeutic attitude in
the follow-up.
Moreover, studying PAF-AH metabolic pathway may
help to better explain the pathogenesis of APS and to
improve management and interpretation of aPL-related
issues, from the analytical results, to the final therapeutic
decision.
We and others recently demonstrated an important role
of aPS/PT antibodies in the serological diagnosis of APS
[5, 26]; however, the therapeutic management of patients
characterized by the presence of isolated aPS/PT remains
an open issue. Patients with isolated aPS/PT antibodies
disclosed lower, BDs-like, PAF-AH as compared to
patients with positive ab2GPI antibodies. Nevertheless,
aPS/PT antibodies may exert their distinct pathogenic role
through pathways in which PAF-AH is not involved.
Anyhow, in case aPS/PT IgG (but not IgM) are combined
to ab2GPI IgG antibodies, PAF-AH tends to be further up-
regulated.
In conclusion, the prognostic information conveyed by
plasmatic PAF-AH activity in patients with positive aPL
antibodies appeared to be independent of common lipid
metabolic markers (i.e. LDL), as previously reported by
other authors in the context of patients with major coronary
events [11]. The major international scientific societies of
cardiologists have included the measurement of PAF-
AH activity among the biomarkers useful in risk stratifi-
cation of adult asymptomatic patients at intermediate car-
diovascular risk in their guidelines [27].
Our data are encouraging, but since some cohort com-
parison include partially overlapping data, a definite utility
of PAF-AH plasmatic activity as a new prognostic bio-
marker also in patients with aPL antibodies and/or definite
APS is actually precluded. For this reason further
prospective studies on selected patients are ongoing.
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